Diagnostic imaging of dopamine receptors in pituitary adenomas.
Dopamine D2 receptor scintigraphy of pituitary adenomas is feasible by single-photon emission computed tomography using (123)I-S-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-iodo-6-methoxybenzamide ((123)I-IBZM) and (123)I-epidepride. (123)I-epidepride is generally superior to (123)I-IBZM for the visualization of D2 receptors on pituitary macroadenomas. However, (123)I-IBZM and (123)I-epidepride scintigraphy are generally not useful to predict the response to dopaminergic treatment in pituitary tumour patients. These techniques might allow discrimination of non-functioning pituitary macroadenomas from other non-tumour pathologies in the sellar region. Dopamine D2 receptors on pituitary tumours can also be studied using positron emission tomography with (11)C-N-raclopride and (11)C-N-methylspiperone.
de Herder
Wouter W
WW
Reijs
Ambroos E M
AEM
Feelders
Richard A
RA
van Aken
Maarten O
MO
Krenning
Eric P
EP
van der Lely
Aart-Jan
AJ
Kwekkeboom
Dik J
DJ
D000236:Adenoma / Q000000981:diagnostic imaging*; D001549:Benzamides; D018492:Dopamine Antagonists; D006801:Humans; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D018492:Dopamine Antagonists; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C063525:epidepride; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide